Sana Biotechnology (SANA) Earnings Analysis
Sana Biotechnology (SANA) next reports earnings on 2026-08-10, consensus EPS -0.15 USD. Last quarter (2026-05-11) it beat with EPS -0.14 USD vs -0.15 USD est (+6.7%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E -3.35.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does SANA next report earnings?
| Next earnings date | 2026-08-10 |
|---|---|
| Consensus EPS estimate | -0.15 USD |
| Revenue estimate | n/a |
SANA earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-11 | -0.14 USD | -0.15 USD | +6.7% | Beat |
| 2026-03-03 | -0.16 USD | -0.13 USD | -23.1% | Miss |
| 2025-11-06 | -0.15 USD | -0.18 USD | +16.7% | Beat |
| 2025-08-11 | -0.16 USD | -0.2 USD | +20% | Beat |
| 2025-03-17 | -0.23 USD | -0.25 USD | +8% | Beat |
| 2024-11-08 | -0.25 USD | -0.26 USD | +3.8% | Beat |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
SANA valuation and analyst view
| Trailing P/E | -3.35 |
|---|---|
| Trailing EPS | -0.87405 USD |
| Price / book | 7.24 |
| Dividend yield | 0.00% |
| Market cap | 0.87B |
| Analyst consensus | Buy (9 buy / 2 hold / 0 sell) |
| Avg price target | 8.5 USD |
Related research pages
Frequently asked questions
When is Sana Biotechnology (SANA)'s next earnings date?
Sana Biotechnology is next scheduled to report on 2026-08-10, with a consensus EPS estimate of -0.15 USD.
Did SANA beat earnings last quarter?
In its 2026-05-11 report, SANA posted EPS of -0.14 USD versus a -0.15 USD estimate — a beat of 6.7%.
What is SANA's earnings track record?
Over the last 6 reported quarters with consensus data, SANA beat estimates 5 times (83%).
What is SANA's current P/E ratio and EPS?
SANA trades at a trailing P/E of -3.35 on trailing EPS of -0.8740536596642298 USD.
What do analysts rate SANA?
Analyst consensus is "Buy" across 11 ratings (0 strong buy, 9 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 8.5 USD.